MedTrace Logo

Monitoring Alectinib Treatment by Detection of ALK Translocations in Serial Blood Samples From Non-Small Cell Lung Cancer Patients

NCT04708639 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2021-02-02

No results posted yet for this study

Summary

Circulating tumor DNA can be used to monitor the treatment effect and identify developing resistance mutations during ALK directed TKI treatment.

Conditions

  • Lung Cancer
  • ALK Gene Mutation
  • Resistance, Disease
  • Mutation

Interventions

DRUG

Alectinib

Use of ctDNA to establish response and resistance to alectinib.

Sponsors & Collaborators

  • Roche Pharma AG

    collaborator INDUSTRY

  • Aarhus University Hospital

    lead OTHER

Principal Investigators

  • Peter Meldgaard, MD, PhD · Aarhus University Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-06-19
Primary Completion
2022-06-30
Completion
2025-06-30
FDA Drug
Yes

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04708639 on ClinicalTrials.gov